Drug Trial Radar · NCT07600177
Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
Last checked: Nov 20, 2026Latest source record: May 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
May 5, 2026
Primary completion
Dec 31, 2026
Study completion Mar 15, 2027
Sponsor
- Lead sponsor
- Oregon Health and Science UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Saint Lukes Hospital Mid America Heart Institute; Cytokinetics
- First posted
- May 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an investigator-initiated two-center study. The goal of this study is to investigate the feasibility, safety and efficacy outcomes of a seamless transition from mavacamten to aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM).
Conditions
- Hypertrophic Cardiomyopathy (HCM)
Interventions
AficamtenDrug
Patients will be switched from mavacamten to aficamten. Mavacamten will be stopped at enrollment, and aficamten started 2 weeks later.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety EndpointsTime frame: Up to 16 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
St. Luke's Hospital - Mid America Heart Institute
Kansas City, Missouri · Not yet recruiting
Oregon Health & Science University
Portland, Oregon · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.